Latest News and Press Releases
Want to stay updated on the latest news?
-
- Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury - - Xequel Launches New Corporate Website with Focus on Novel Peptide Platform for Ophthalmology,...
-
CHARLESTON, S.C. and FORT WORTH, Texas, July 26, 2022 (GLOBE NEWSWIRE) -- Xequel Bio, Inc., a clinical stage biopharmaceutical company developing dermatologic and ophthalmic therapeutics utilizing...
-
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet...
-
- Jerry St. Peter Named Chief Executive Officer and Member of the Board of Directors- Wes Brazell Named Chief Financial Officer- Executives Bring Significant Global Biopharmaceutical Development and...